The protective effect of HIV-2 infection: Implications for understanding HIV-1 immunity

AIDS

Volumn 28, Issue 7, 2014, Pages 1065-1067

  Kanki, Phyllis J ^a   Rowland Jones, Sarah ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIV 1; HIV 2; HIV dual infection; mortality; survival

Indexed keywords

GAG PROTEIN;

CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOPATHOLOGY; NOTE; PRIORITY JOURNAL; SURVIVAL TIME; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MALE; MIXED INFECTION; MORTALITY; VIROLOGY;

COINFECTION; FEMALE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE;

EID: 84897477182     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000209     Document Type: Note

References (62)

1. Barin F, Mboup S, Denis F, Kanki PJ, Allan JS, Lee TH, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. Lancet 1985; ii:1387-1390.
2. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343-346.
3. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Gueye-Ndiaye A, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943-946.
4. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development with HIV-2 compared to HIV-1. Science 1994; 265:1587-1590.
5. Schim van der Loeff M, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, et al. Undetectable plasma viral load predicts normal survival in HIV-2 infected people in a West African village. Retrovirology 2010; 7:46.
6. Travers K, MBoup S, Marlink RG, Gueye-Ndiaye A, Siby T, Thior I, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612-1615.
7. Travers KU, Eisen GE, Marlink RG, Essex ME, Hsieh CC, Mboup S, et al. Protection from HIV-1 infection by HIV-2. AIDS 1998; 12:223-226.
8. Ariyoshi K, Schim van der Loeff M, Sabally S, Cham F, Corrah T, Whittle H. Does HIV-2 infection provide cross-protection against HIV-1 infection? AIDS 1997; 11:1053-1054.
9. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001; 15:2319-2321.
10. Schim van der Loeff M, Aaby P, Aryioshi K, Vincent T, Awasana AA, Da CostaF C, et al. HIV-2 does not protect again HIV-1 infection in a rural community in Guinea-Bissau. AIDS 2001; 15:2303-2310.
11. Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol 2013; 23:221-240.
12. Esbjörnsson J, Mansson F, Kvist A, Isberg P-E, Biague AJ, da Silva ZJ, et al. Increased survival among HIV-1 and HIV-2 dualinfected individuals compared to HIV-1 single-infected individuals. AIDS 2014; 28:949-957.
13. Poulsen AG, Aaby P, Frederiksen K, Kvinesdal B, Molbak K, Dias F, et al. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet 1989; 333:827-831.
14. Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012; 367: 224-232.
15. Prince PD, Matser A, Van Tienen C, Whittle HC, Schim Van Der Loeff MF. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS 2013 [Epub ahead of print].
16. Yindom LM, Leligdowicz A, Martin MP, Gao X, Qi Y, Zaman SMA, et al. Influence of HLA class 1 and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression on a Manjako community in West Africa. J Virol 2010; 84:8202-8213.
17. WHO. Acquired immunodeficiency syndrome (AIDS). Proposed WHO criteria for interpreting results from western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II. Wkly Epidemiol Rec 1990; 65:281-283.
18. Walther-Jallow L, Andersson S, da Silva Z, Biberfeld G. High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses 1999; 15:957-962.
19. Akimoto H, Kaneko H, Sekigawa I, Hashimoto H, Kaneko Y, Yamamoto N. Binding of HIV-2 envelope glycoprotein to CD8 molecules and related beta-chemokine production. Immunology 1998; 95:214-218.
20. Kokkotou EG, Sankalé JL, Mani I, Gueye-Ndiaye A, Schwartz D, Essex M, et al. In vitro correlates of HIV-2 mediated HIV-1 protection. Proc Natl Acad Sci USA 2000; 97:6797-6802.
21. Dieng Sarr A, Lu Y, Sankalé JL, Eisen G, Popper S, Mboup S, et al. Robust HIV Type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay. AIDS Res Hum Retroviruses 2001; 17:1257-1264.
22. De Silva TI, Peng Y, Leligdowicz A, Zaidi I, Li L, Griffin H, et al. Correlates of T-cell-mediated viral control and phenotype if CD8RT cells in HIV-1, a naturally contained human retroviral infection. Blood 2013; 121:4330-4339.
23. Shea A, Dieng-Sarr A, Jones N, Penning L, Eisen G, Gueye-Ndiaye A, et al. CCR5 receptor expression is down-regulated in HIV-2 infection: implication for viral control and protection. AIDS Res Hum Retroviruses 2004; 20:630-635.
24. Zheng NN, McElrath MJ, Sow PS, Hawes SE, Diallo-Agne H, Stern JE, et al. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J Virol 2007; 81:9061-9071.
25. Leligdowicz A, Onyango C, Yindom LM, Peng Y, Cotton M, Jaye A, et al. Highly avid, oligoclonal, early-differentiated antigen-specific CD8R T cells in chronic HIV-2 infection. Eur J Immunol 2010; 40:1963-1972.
26. Rodriguez SK, Dieng-Sarr A, MacNeil A, Meloni S, Gueye-Ndiaye A, Traore I, et al. Comparison of heterologous neutralizing antibody responses between HIV-1 and HIV-2 infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2. J Virol 2007; 81:5331-5338.
27. De Silva TI, Aasa-Chapman M, Cotton M, Hué S Robinson J, Bibollet-Ruche F, et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol 2012; 86: 930-946.
28. Popper SJ, Dieng-Sarr A, Travers KU, Gueye-Ndiaye A, Mboup S, Essex M, et al. Lower HIV-2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 18:1116-1121.
29. Smallman-Raynor M, Cliff A. The spread of human immunodeficiency virus type 2 into Europe: a geographical analysis. Int J Epidemiol 1991; 20:480-489.
30. Anderson RM, May RM. The population biology of the interaction between HIV-1 and HIV-2: coexistence or competitive exclusion? AIDS 1996; 10:1663-1673.
31. Forbi JC, Esona MD, Iperepolu HO, Adoga MP, Agwale S. Absence of routine molecular testing and prevalence of HIV-2 infection in regions hardest-hit by HIV infection. J Infect Dev Ctries 2012; 6:854-859.
32. Barin F, Mboup S, Denis F, Kanki PJ, Allan JS, Lee TH, et al. Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa. Lancet 1985; ii:1387-1390.
33. Clavel F, Guetard D, Brun-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343-346.
34. Kanki PJ, Travers KU, Mboup S, Hsieh CC, Marlink RG, Gueye-Ndiaye A, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943-946.
35. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of disease development with HIV-2 compared to HIV-1. Science 1994; 265:1587-1590.
36. Schim van der Loeff M, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, et al. Undetectable plasma viral load predicts normal survival in HIV-2 infected people in a West African village. Retrovirology 2010; 7:46.
37. Travers K, MBoup S, Marlink RG, Gueye-Ndiaye A, Siby T, Thior I, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995; 268:1612-1615.
38. Travers KU, Eisen GE, Marlink RG, Essex ME, Hsieh CC, Mboup S, et al. Protection from HIV-1 infection by HIV-2. AIDS 1998; 12:223-226.
39. Ariyoshi K, Schim van der Loeff M, Sabally S, Cham F, Corrah T, Whittle H. Does HIV-2 infection provide cross-protection against HIV-1 infection? AIDS 1997; 11:1053-1054.
40. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001; 15:2319-2321.
41. Schim van der Loeff M, Aaby P, Aryioshi K, Vincent T, Awasana AA, Da CostaF C, et al. HIV-2 does not protect again HIV-1 infection in a rural community in Guinea-Bissau. AIDS 2001; 15:2303-2310.
42. Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol 2013; 23:221-240.
43. Esbjörnsson J, Mansson F, Kvist A, Isberg P-E, Biague AJ, da Silva ZJ, et al. Increased survival among HIV-1 and HIV-2 dualinfected individuals compared to HIV-1 single-infected individuals. AIDS 2014; 28:949-957.
44. Poulsen AG, Aaby P, Frederiksen K, Kvinesdal B, Molbak K, Dias F, et al. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet 1989; 333:827-831.
45. Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 2012; 367: 224-232.
46. Prince PD, Matser A, Van Tienen C, Whittle HC, Schim Van Der Loeff MF. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS 2013 [Epub ahead of print].
47. Yindom LM, Leligdowicz A, Martin MP, Gao X, Qi Y, Zaman SMA, et al. Influence of HLA class 1 and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression on a Manjako community in West Africa. J Virol 2010; 84:8202-8213.
48. WHO. Acquired immunodeficiency syndrome (AIDS). Proposed WHO criteria for interpreting results from western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II. Wkly Epidemiol Rec 1990; 65:281-283.
49. Walther-Jallow L, Andersson S, da Silva Z, Biberfeld G. High concordance between polymerase chain reaction and antibody testing of specimens from individuals dually infected with HIV types 1 and 2 in Guinea-Bissau, West Africa. AIDS Res Hum Retroviruses 1999; 15:957-962.
50. Akimoto H, Kaneko H, Sekigawa I, Hashimoto H, Kaneko Y, Yamamoto N. Binding of HIV-2 envelope glycoprotein to CD8 molecules and related beta-chemokine production. Immunology 1998; 95:214-218.
51. Kokkotou EG, Sankalé JL, Mani I, Gueye-Ndiaye A, Schwartz D, Essex M, et al. In vitro correlates of HIV-2 mediated HIV-1 protection. Proc Natl Acad Sci USA 2000; 97:6797-6802.
52. Dieng Sarr A, Lu Y, Sankalé JL, Eisen G, Popper S, Mboup S, et al. Robust HIV Type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay. AIDS Res Hum Retroviruses 2001; 17:1257-1264.
53. De Silva TI, Peng Y, Leligdowicz A, Zaidi I, Li L, Griffin H, et al. Correlates of T-cell-mediated viral control and phenotype if CD8RT cells in HIV-1, a naturally contained human retroviral infection. Blood 2013; 121:4330-4339.
54. Shea A, Dieng-Sarr A, Jones N, Penning L, Eisen G, Gueye-Ndiaye A, et al. CCR5 receptor expression is down-regulated in HIV-2 infection: implication for viral control and protection. AIDS Res Hum Retroviruses 2004; 20:630-635.
55. Zheng NN, McElrath MJ, Sow PS, Hawes SE, Diallo-Agne H, Stern JE, et al. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J Virol 2007; 81:9061-9071.
56. Leligdowicz A, Onyango C, Yindom LM, Peng Y, Cotton M, Jaye A, et al. Highly avid, oligoclonal, early-differentiated antigen-specific CD8R T cells in chronic HIV-2 infection. Eur J Immunol 2010; 40:1963-1972.
57. Rodriguez SK, Dieng-Sarr A, MacNeil A, Meloni S, Gueye-Ndiaye A, Traore I, et al. Comparison of heterologous neutralizing antibody responses between HIV-1 and HIV-2 infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2. J Virol 2007; 81:5331-5338.
58. De Silva TI, Aasa-Chapman M, Cotton M, Hué S Robinson J, Bibollet-Ruche F, et al. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol 2012; 86: 930-946.
59. Popper SJ, Dieng-Sarr A, Travers KU, Gueye-Ndiaye A, Mboup S, Essex M, et al. Lower HIV-2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 18:1116-1121.
60. Smallman-Raynor M, Cliff A. The spread of human immunodeficiency virus type 2 into Europe: a geographical analysis. Int J Epidemiol 1991; 20:480-489.
61. Anderson RM, May RM. The population biology of the interaction between HIV-1 and HIV-2: coexistence or competitive exclusion? AIDS 1996; 10:1663-1673.
62. Forbi JC, Esona MD, Iperepolu HO, Adoga MP, Agwale S. Absence of routine molecular testing and prevalence of HIV-2 infection in regions hardest-hit by HIV infection. J Infect Dev Ctries 2012; 6:854-859.